【摘要】 目的:了解中山市人民医院(以下简称"我院")口服降糖药的应用情况,为临床口服降糖药的合理应用提供参考。方法:采用世界卫生组织推荐的限定日剂量法,对2011—2013年我院口服降糖药的应用情况进行回顾性分析。结果:2011—2013年我院口服降糖药的销售金额呈逐年递增趋势(从2011年的519万元增至2013年的1 126万元),其占药品销售总金额的比例也逐年上升(从2011年的0.90%上升至2013年的1.46%)。各类口服降糖药的销售金额、用药频度均逐年增加,磺酰脲类促胰岛素分泌剂为临床常用品种,其DDDs排序稳居首位。二甲双胍片的用药频度排序逐年上升;阿卡波糖片在2012—2013年连续2年销售金额排序居第1位;新引进的西格列汀片销售金额和用药频度的同步性较好。结论:2011—2013年我院口服降糖药中,α-葡萄糖苷酶抑制剂和磺酰脲类促胰岛素分泌剂占主导地位,我院口服降糖药的应用基本合理。更多还原

【Abstract】 OBJECTIVE: To investigate the use of oral hypoglycemic agents in Zhongshan Municipal People’s Hospital( hereinafter referred to as "our hospital") to provide reference for clinical rational use of oral hypoglycemic agents. METHODS: The use of oral hypoglycemic agents during 2011-2013 was analyzed retrospectively using the defined daily dose method recommended by WHO. RESULTS: The consumption sum and DDDs of oral hypoglycemic drugs in our hospital increased year by year,up from 5. 19 million Yuan in 2011 to 11. 26 million Yuan in 2013,and its ratio in total drug consumption sum was also increased year by year,up from 0. 90% in 2011 to 1. 46% of 2013.The consumption sum and the DDDs of different oral hypoglycemic agents increased year by year. Sulfonylurea was frequently used oral hypoglycemic agents,and it remained at the first place in DDDs rank. The DDDs of metformin increased year by year; acarbose dominated the first place from 2012 to 2013; the consumption sum and DDDs of the newly introduced sitagliptin were well-synchronized. CONCLUSIONS: During 2011-2013 period, α-glucosidase inhibitor and sulfonylurea drugs dominated the list of the oral hypoglycemic drugs in our hospital. The use of oral hypoglycemic agents in our hospital was rational on the whole.更多还原